<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562484</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-USF-06-28</org_study_id>
    <nct_id>NCT00562484</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults</brief_title>
  <acronym>CSL's IVV</acronym>
  <official_title>A Phase IV, Randomized, Observer-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in Adults Aged ≥ 18 to &lt; 65 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <brief_summary>
    <textblock>
      This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza
      Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a
      population defined as being not at risk of severe complications following influenza
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CSL's IVV Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection</measure>
    <time_frame>2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009</time_frame>
    <description>Incidence of Laboratory Confirmed Influenza A/B infection was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.
Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / placebo recipient infection rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSL's IVV Vaccine Efficacy Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection Due to Strains Matched to Vaccine Strains</measure>
    <time_frame>2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009</time_frame>
    <description>Incidence of laboratory confirmed influenza A/B infection due to strains matched to vaccine strains was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.
Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / Placebo recipient infection rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Influenza-like Illness (ILI)</measure>
    <time_frame>2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009</time_frame>
    <description>The criteria for the protocol defined ILI were as follows:
At least one respiratory symptom:
cough, sore throat or nasal congestion
And at least one systemic symptom:
fever (as defined by oral temperature ≥ 37.8°C (100.0°F), or feverishness (as defined by participant's subjective feeling of fever), chills or body aches.
The CDC ILI case definition was the occurrence of fever (100°F [37.8°C] or higher) in conjunction with either cough or sore throat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2008</measure>
    <time_frame>21 days after study vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2009</measure>
    <time_frame>21 days after study vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2008</measure>
    <time_frame>21 days after study vaccination</time_frame>
    <description>Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer &lt; 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2009</measure>
    <time_frame>21 days after study vaccination</time_frame>
    <description>Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer &lt; 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Increase in HI Titer 21 Days After Study Vaccination, Year 2008</measure>
    <time_frame>21 days after study vaccination</time_frame>
    <description>Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Increase in HI Titer Rate 21 Days After Study Vaccination, Year 2009</measure>
    <time_frame>21 days after study vaccination</time_frame>
    <description>Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Local and Systemic Solicited Symptoms</measure>
    <time_frame>5 days after study vaccination</time_frame>
    <description>Adverse event grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.
Fever Grade 1: ≥ 37.7°C - &lt; 38.0°C (≥ 99.9 - &lt; 100.4°F) Grade 2: ≥ 38.0°C - &lt; 39.0°C (≥ 100.4 - &lt; 102.2°F) Grade 3: ≥ 39.0°C (&gt; 102.2°F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</measure>
    <time_frame>21 days after study vaccination</time_frame>
    <description>UAE grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs)</measure>
    <time_frame>180 days after study vaccination</time_frame>
    <description>An SAE was any untoward medical occurrence that at any dose:
Resulted in death;
Was life-threatening;
Required an unexpected in-participant hospitalization or prolongation of existing hospitalization;
Resulted in persistent or significant disability / incapacity;
Was a congenital anomaly / birth defect; and / or
Was medically significant (defined as an event that did not necessarily meet any of the SAE criteria, but was judged by the treating physician to potentially jeopardize the participant or require medical intervention to prevent one of the out</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Onsets of Chronic Illness (NOCI)</measure>
    <time_frame>180 days after study vaccination</time_frame>
    <description>An NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7500</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL Limited Influenza Vaccine</intervention_name>
    <description>A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females aged ≥ 18 to &lt; 65 years at the time of vaccination

          -  Non pregnant/ non lactating females

        Exclusion Criteria:

          -  Hypersensitivity to influenza vaccine or allergy to any components of the Study
             Vaccines

          -  Vaccination against influenza in the previous 6 months

          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality

          -  Known history of Guillain-Barré Syndrome;

          -  Clinical signs of active infection and/or an oral temperature of ≥ 37.8 oC.

          -  History of neurological disorders or seizures

          -  Confirmed or suspected immunosuppressive condition or a previously diagnosed
             immunodeficiency disorder

          -  Current or recent immunosuppressive or immunomodulative therapy, including systemic
             corticosteroids

          -  Administration of immunoglobulins and/or any blood products;

          -  Participation in a clinical trial or use of an investigational compound;

          -  Vaccination with a registered vaccine within 14 days (for inactivated vaccines) or 28
             days (for live vaccines) prior;

          -  Participants indicated to receive an influenza vaccine on an annual basis according to
             the local public health recommendations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Clinical Trials Unit, Canberra Hospital</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Organisation</name>
      <address>
        <city>Brookvale</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Organisation</name>
      <address>
        <city>Caringbah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Area Health Service, Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Centre for Immunisation Research &amp; Surveillance (NCIRS) The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Organisation</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trialworks Clinical Research Services</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Organisation Caboolture Clinical Research Centre</name>
      <address>
        <city>Caboolture</city>
        <state>Queensland</state>
        <zip>4510</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Medicine, James Cook University, Cairns Base Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Organisation</name>
      <address>
        <city>Kippa Ring</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMAX, a division of IDT Australia</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paediatric Trials Unit, Women's and Children's Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Old Port Road Medical and Dental Centre</name>
      <address>
        <city>Royal Park</city>
        <state>South Australia</state>
        <zip>5014</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sexual Health Service</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barwon Health, Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Institute of Western Australia</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>198 Youth Health Centre</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Trials</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RMC Medical Centre</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <results_first_submitted>July 8, 2011</results_first_submitted>
  <results_first_submitted_qc>August 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2011</results_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CSL's IVV</title>
          <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10033"/>
                <participants group_id="P2" count="5011"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9827"/>
                <participants group_id="P2" count="4907"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="206"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved away from the study area</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not provided or not specified</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CSL's IVV</title>
          <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10033"/>
            <count group_id="B2" value="5011"/>
            <count group_id="B3" value="15044"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10033"/>
                    <measurement group_id="B2" value="5011"/>
                    <measurement group_id="B3" value="15044"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="14.69"/>
                    <measurement group_id="B2" value="35.4" spread="14.69"/>
                    <measurement group_id="B3" value="35.5" spread="14.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5523"/>
                    <measurement group_id="B2" value="2667"/>
                    <measurement group_id="B3" value="8190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4510"/>
                    <measurement group_id="B2" value="2344"/>
                    <measurement group_id="B3" value="6854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8201"/>
                    <measurement group_id="B2" value="4090"/>
                    <measurement group_id="B3" value="12291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1832"/>
                    <measurement group_id="B2" value="921"/>
                    <measurement group_id="B3" value="2753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CSL's IVV Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection</title>
        <description>Incidence of Laboratory Confirmed Influenza A/B infection was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.
Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / placebo recipient infection rate.</description>
        <time_frame>2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009</time_frame>
        <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>CSL's IVV Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection</title>
          <description>Incidence of Laboratory Confirmed Influenza A/B infection was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.
Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / placebo recipient infection rate.</description>
          <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9889"/>
                <count group_id="O2" value="4960"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" lower_limit="1.97" upper_limit="2.57"/>
                    <measurement group_id="O2" value="3.87" lower_limit="3.37" upper_limit="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy = 100 x (1 - ratio of incidence rate)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30</ci_lower_limit>
            <ci_upper_limit>52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSL's IVV Vaccine Efficacy Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection Due to Strains Matched to Vaccine Strains</title>
        <description>Incidence of laboratory confirmed influenza A/B infection due to strains matched to vaccine strains was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.
Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / Placebo recipient infection rate.</description>
        <time_frame>2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009</time_frame>
        <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>CSL's IVV Vaccine Efficacy Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection Due to Strains Matched to Vaccine Strains</title>
          <description>Incidence of laboratory confirmed influenza A/B infection due to strains matched to vaccine strains was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.
Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / Placebo recipient infection rate.</description>
          <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9889"/>
                <count group_id="O2" value="4960"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" lower_limit="0.45" upper_limit="0.76"/>
                    <measurement group_id="O2" value="1.47" lower_limit="1.17" upper_limit="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy = 100 x (1 - ratio of incidence rate)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine efficacy</param_type>
            <param_value>60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44</ci_lower_limit>
            <ci_upper_limit>72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Influenza-like Illness (ILI)</title>
        <description>The criteria for the protocol defined ILI were as follows:
At least one respiratory symptom:
cough, sore throat or nasal congestion
And at least one systemic symptom:
fever (as defined by oral temperature ≥ 37.8°C (100.0°F), or feverishness (as defined by participant’s subjective feeling of fever), chills or body aches.
The CDC ILI case definition was the occurrence of fever (100°F [37.8°C] or higher) in conjunction with either cough or sore throat.</description>
        <time_frame>2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009</time_frame>
        <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Influenza-like Illness (ILI)</title>
          <description>The criteria for the protocol defined ILI were as follows:
At least one respiratory symptom:
cough, sore throat or nasal congestion
And at least one systemic symptom:
fever (as defined by oral temperature ≥ 37.8°C (100.0°F), or feverishness (as defined by participant’s subjective feeling of fever), chills or body aches.
The CDC ILI case definition was the occurrence of fever (100°F [37.8°C] or higher) in conjunction with either cough or sore throat.</description>
          <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9889"/>
                <count group_id="O2" value="4960"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reported ILI (protocol definition)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Culture-confirmed ILI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reported ILI (CDC definition)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laboratory-confirmed ILI (CDC definition)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2008</title>
        <time_frame>21 days after study vaccination</time_frame>
        <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2008</title>
          <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Solomon Islands/3/2006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="42" lower_limit="34" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (A/Brisbane/10/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="35" lower_limit="27" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Brisbane/3/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="72" upper_limit="82"/>
                    <measurement group_id="O2" value="13" lower_limit="8" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2009</title>
        <time_frame>21 days after study vaccination</time_frame>
        <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2009</title>
          <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Brisbane/59/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="90" upper_limit="96"/>
                    <measurement group_id="O2" value="36" lower_limit="28" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (A/Uruguay/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="90" upper_limit="96"/>
                    <measurement group_id="O2" value="43" lower_limit="35" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Florida/4/2006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="85" upper_limit="93"/>
                    <measurement group_id="O2" value="30" lower_limit="23" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2008</title>
        <description>Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer &lt; 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.</description>
        <time_frame>21 days after study vaccination</time_frame>
        <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2008</title>
          <description>Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer &lt; 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.</description>
          <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Solomon Islands/3/2006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="76" upper_limit="85"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (A/Brisbane/10/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="82" upper_limit="90"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Brisbane/3/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="57" upper_limit="69"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2009</title>
        <description>Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer &lt; 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.</description>
        <time_frame>21 days after study vaccination</time_frame>
        <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2009</title>
          <description>Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer &lt; 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.</description>
          <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Brisbane/59/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="72" upper_limit="82"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (A/Uruguay/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="76" upper_limit="85"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Florida/4/2006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="55" upper_limit="67"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Increase in HI Titer 21 Days After Study Vaccination, Year 2008</title>
        <description>Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.</description>
        <time_frame>21 days after study vaccination</time_frame>
        <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase in HI Titer 21 Days After Study Vaccination, Year 2008</title>
          <description>Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.</description>
          <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
          <units>Fold increase</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Solomon Islands/3/2006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="17" upper_limit="26"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (A/Brisbane/10/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Brisbane/3/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Increase in HI Titer Rate 21 Days After Study Vaccination, Year 2009</title>
        <description>Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.</description>
        <time_frame>21 days after study vaccination</time_frame>
        <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase in HI Titer Rate 21 Days After Study Vaccination, Year 2009</title>
          <description>Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.</description>
          <population>Evaluable Population for the Clinical Endpoint Analysis consisted of all participants who: received study vaccine and clinical endpoint follow-up was longer than 14 days after vaccination; and had not taken any contraindicated medications during the On-study or Clinical Endpoint Periods as potentially impacting clinical endpoint assessments.</population>
          <units>Fold increase</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 (A/Brisbane/59/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="16"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 (A/Uruguay/2007)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="13" upper_limit="18"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (B/Florida/4/2006)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="7"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Local and Systemic Solicited Symptoms</title>
        <description>Adverse event grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.
Fever Grade 1: ≥ 37.7°C - &lt; 38.0°C (≥ 99.9 - &lt; 100.4°F) Grade 2: ≥ 38.0°C - &lt; 39.0°C (≥ 100.4 - &lt; 102.2°F) Grade 3: ≥ 39.0°C (&gt; 102.2°F)</description>
        <time_frame>5 days after study vaccination</time_frame>
        <population>Safety Population comprised all participants who received study vaccine (CSL’s IVV or placebo) and provided at least one safety assessment after the vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Local and Systemic Solicited Symptoms</title>
          <description>Adverse event grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.
Fever Grade 1: ≥ 37.7°C - &lt; 38.0°C (≥ 99.9 - &lt; 100.4°F) Grade 2: ≥ 38.0°C - &lt; 39.0°C (≥ 100.4 - &lt; 102.2°F) Grade 3: ≥ 39.0°C (&gt; 102.2°F)</description>
          <population>Safety Population comprised all participants who received study vaccine (CSL’s IVV or placebo) and provided at least one safety assessment after the vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10015"/>
                <count group_id="O2" value="5005"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7474"/>
                    <measurement group_id="O2" value="1021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4850"/>
                    <measurement group_id="O2" value="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6956"/>
                    <measurement group_id="O2" value="874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling / induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling / induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4670"/>
                    <measurement group_id="O2" value="1955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2553"/>
                    <measurement group_id="O2" value="1176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2916"/>
                    <measurement group_id="O2" value="1277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2150"/>
                    <measurement group_id="O2" value="609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509"/>
                    <measurement group_id="O2" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="678"/>
                    <measurement group_id="O2" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</title>
        <description>UAE grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.</description>
        <time_frame>21 days after study vaccination</time_frame>
        <population>Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Unsolicited Adverse Events (UAEs)</title>
          <description>UAE grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.</description>
          <population>Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9889"/>
                <count group_id="O2" value="4960"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3519"/>
                    <measurement group_id="O2" value="1698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reported Grade 1 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1604"/>
                    <measurement group_id="O2" value="750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reported Grade 2 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1536"/>
                    <measurement group_id="O2" value="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reported Grade 3 UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events (SAEs)</title>
        <description>An SAE was any untoward medical occurrence that at any dose:
Resulted in death;
Was life-threatening;
Required an unexpected in-participant hospitalization or prolongation of existing hospitalization;
Resulted in persistent or significant disability / incapacity;
Was a congenital anomaly / birth defect; and / or
Was medically significant (defined as an event that did not necessarily meet any of the SAE criteria, but was judged by the treating physician to potentially jeopardize the participant or require medical intervention to prevent one of the out</description>
        <time_frame>180 days after study vaccination</time_frame>
        <population>Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events (SAEs)</title>
          <description>An SAE was any untoward medical occurrence that at any dose:
Resulted in death;
Was life-threatening;
Required an unexpected in-participant hospitalization or prolongation of existing hospitalization;
Resulted in persistent or significant disability / incapacity;
Was a congenital anomaly / birth defect; and / or
Was medically significant (defined as an event that did not necessarily meet any of the SAE criteria, but was judged by the treating physician to potentially jeopardize the participant or require medical intervention to prevent one of the out</description>
          <population>Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9889"/>
                <count group_id="O2" value="4960"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number rof participants with related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Onsets of Chronic Illness (NOCI)</title>
        <description>An NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension).</description>
        <time_frame>180 days after study vaccination</time_frame>
        <population>Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL's IVV</title>
            <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
          </group>
        </group_list>
        <measure>
          <title>New Onsets of Chronic Illness (NOCI)</title>
          <description>An NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension).</description>
          <population>Safety Population comprised all participants who received study vaccine (CSL's IVV or placebo) and provided at least one safety assessment after the vaccination.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9889"/>
                <count group_id="O2" value="4960"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with related NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>21 days after study vaccination for unsolicited adverse events and 180 days after study vaccination for serious adverse events.</time_frame>
      <desc>Other adverse events presented were unsolicited adverse events up to 21 days after study vaccination</desc>
      <group_list>
        <group group_id="E1">
          <title>CSL's IVV</title>
          <description>Participants received a dose of the 2008 or 2009 Southern Hemisphere formulation of CSL's IVV</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received a dose of placebo in either 2008 or 2009 Southern Hemisphere influenza season</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="10015"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Bicuspid aortic valve</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Trisomy 21</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Umbilical hernia obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Uvulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="10015"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10015"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10015"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Herpes simplex hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Anaesthetic complication pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Heart injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>B precursor type acute leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Colon cancer stage II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Borderline ovarian tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cervical myelopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Renal cyst ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Tracheal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3028" subjects_at_risk="10015"/>
                <counts group_id="E2" subjects_affected="1549" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="402" subjects_affected="387" subjects_at_risk="10015"/>
                <counts group_id="E2" events="205" subjects_affected="201" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="113" subjects_affected="110" subjects_at_risk="10015"/>
                <counts group_id="E2" events="56" subjects_affected="55" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="155" subjects_affected="135" subjects_at_risk="10015"/>
                <counts group_id="E2" events="78" subjects_affected="70" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1567" subjects_affected="1128" subjects_at_risk="10015"/>
                <counts group_id="E2" events="712" subjects_affected="558" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="148" subjects_affected="144" subjects_at_risk="10015"/>
                <counts group_id="E2" events="77" subjects_affected="73" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="529" subjects_affected="501" subjects_at_risk="10015"/>
                <counts group_id="E2" events="276" subjects_affected="258" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="273" subjects_affected="248" subjects_at_risk="10015"/>
                <counts group_id="E2" events="160" subjects_affected="150" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="228" subjects_affected="220" subjects_at_risk="10015"/>
                <counts group_id="E2" events="112" subjects_affected="104" subjects_at_risk="5005"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="163" subjects_affected="155" subjects_at_risk="10015"/>
                <counts group_id="E2" events="82" subjects_affected="80" subjects_at_risk="5005"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Study Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

